Pacritinib real-world study for myelofibrosis
Part of Blood & lymphatic clinical trials.
This study looks at how well pacritinib works in everyday medical care for people with myelofibrosis, a type of bone marrow cancer that causes scarring. It reviews medical records to understand treatment effects, which may help guide future care decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have a diagnosis of myelofibrosis.
- You have been taking pacritinib for at least one month.
- You have not had leukemia before or a condition that turns into leukemia.
- You have not taken two or more JAK inhibitor medications in the past.
- You are not taking pacritinib as part of a clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if pacritinib, a JAK inhibitor, can help people with myelofibrosis who also have low platelet counts. It may be an option for those who haven't had JAK inhibitor therapy before or who didn't respond to a previous one.
This study tests a new combination of two drugs, tagraxofusp and pacritinib, for people with myelofibrosis who have already tried a JAK inhibitor without enough benefit or who couldn't take one. The goal is to see if the combination can shrink the spleen and improve symptoms.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
This trial is studying the effectiveness of momelotinib, a JAK inhibitor, for people with myelofibrosis who have an enlarged spleen. It aims to see how well the drug works in real-world practice.
This trial tests a combination of two drugs, selinexor and pacritinib, for people with myelofibrosis who have not had previous JAK inhibitor treatment and have low red blood cells (anemia) or low platelets. The goal is to see if these drugs can help improve symptoms and reduce spleen size while being safe for patients with cytopenias.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.